Industry news that matters to you.  Learn more

Archives for April 2011

Non-human Sugar Molecule May be a Potential Cancer Biomarker and Treatment

According to researchers at the University of California, San Diego School of Medicine, a non-human sugar molecule commonly found in people may be useful as a future biomarker for predicting cancer risk. Moreover, the potential biomarker may be useful for diagnosing cancer cases early and, in sufficient concentration, used as a treatment for suppressing tumor growth. The study is published in the April 19 online issue of the journal Cancer Research.

Intrinsic Bioprobes Launches Three New CLIA Approved Mass Spectrometry-based Tests for Proteins Implicated in Kidney Disease and Renal Failure

Intrinsic Bioprobes Inc (“IBI”) today announced the launch of its first
mass spectrometry-based protein assays for in-vitro diagnostic testing. The assays for beta-2-microglobulin, cystatin C, and retinol binding protein are performed on IBI’s MASSAY platform at the CLIA-certified and College of American Pathology (CAP) accredited diagnostic laboratory of the Institute of Genomics Medicine, UMDNJ-New Jersey Medical School.

Quintiles to Support Innovative I-Spy 2 Breast Cancer Clinical Trial

Quintiles announced recently that it will contribute a total of $2.6 million over four years to support I-SPY 2, a unique adaptive clinical trial designed to develop breast cancer therapies twice as quickly and at one-fifth the cost of current methods. Current development costs typically exceed $1 billion and take 12 to 15 years to bring a single drug to market.

Clusterin Not a Potential Early Biomarker for Alzheimer’s Disease Development

According to a recent study published in the Journal of the American Medical Association, plasma clusterin levels are significantly associated with prevalence and severity of Alzheimer’s disease (AD), but not with incidence.

NextGen Sciences Launches Multiplex Protein Plasma Biomarker Assay for Breast Cancer

NextGen Group plc recently announced that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its plasmabreast25 multiplex protein assay, targeting breast cancer biomarker discovery and qualification. The assay simultaneously measures 25 human plasma proteins that are thought to have potential as biomarkers in breast cancer.